drugset / Trial / NCT05093231
Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer
Phase 2
Recruiting
20 enrolled
Cambridge University Hospitals NHS Foundation Trust
National Institute for Health Research, United Kingdom · collab
NaSingle-groupOpen-labelTreatment
Summary
A phase II study combining pembrolizumab with olaparib in metastatic pancreatic adenocarcinoma patients with high tumour mutation burden
Timeline
- Start
- 2025-02-26
- Primary completion
- 2027-07-31
- Completion
- 2028-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olaparib | Small molecule | 300 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |